Drug Profile
Research programme: hepatic fibrosis therapy - Pacific Therapeutics
Alternative Names: PTL-303Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pacific Therapeutics
- Class
- Mechanism of Action Antioxidants; Cytokine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatic fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Hepatic-fibrosis in Canada
- 31 Dec 2009 Early research in Hepatic fibrosis in Canada (unspecified route)